MX341117B - Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab. - Google Patents
Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab.Info
- Publication number
- MX341117B MX341117B MX2012002907A MX2012002907A MX341117B MX 341117 B MX341117 B MX 341117B MX 2012002907 A MX2012002907 A MX 2012002907A MX 2012002907 A MX2012002907 A MX 2012002907A MX 341117 B MX341117 B MX 341117B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- autoimmune
- epratuzumab
- inflammatory diseases
- relates
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 230000001363 autoimmune Effects 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 229950009760 epratuzumab Drugs 0.000 title abstract 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 abstract 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24379709P | 2009-09-18 | 2009-09-18 | |
| PCT/EP2010/005225 WO2011032633A1 (en) | 2009-09-18 | 2010-08-26 | Treatment of autoimmune and inflammatory diseases with epratuzumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012002907A MX2012002907A (es) | 2012-04-30 |
| MX341117B true MX341117B (es) | 2016-08-09 |
Family
ID=43063209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002907A MX341117B (es) | 2009-09-18 | 2010-08-26 | Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110070227A1 (index.php) |
| EP (1) | EP2478012B1 (index.php) |
| JP (1) | JP5816905B2 (index.php) |
| KR (1) | KR20120100914A (index.php) |
| CN (1) | CN102574920A (index.php) |
| AU (1) | AU2010294905B2 (index.php) |
| BR (1) | BR112012006035A2 (index.php) |
| CA (1) | CA2774244A1 (index.php) |
| EA (1) | EA026902B1 (index.php) |
| ES (1) | ES2608661T3 (index.php) |
| IN (1) | IN2012DN02196A (index.php) |
| MX (1) | MX341117B (index.php) |
| WO (1) | WO2011032633A1 (index.php) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006259664A1 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| HUE031902T2 (en) | 2008-05-23 | 2017-08-28 | Siwa Corp | Procedures and Preparations to Promote Regeneration |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| LT3682905T (lt) | 2011-10-03 | 2022-02-25 | Modernatx, Inc. | Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas |
| US9757458B2 (en) * | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| SI2906251T1 (en) * | 2012-10-12 | 2018-01-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| CN106414497B (zh) | 2014-05-29 | 2021-07-27 | 宏观基因有限公司 | 三特异性结合分子和其使用方法 |
| CA2961603C (en) * | 2014-09-19 | 2021-07-13 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| DK3677598T3 (da) | 2016-02-19 | 2022-05-30 | Siwa Corp | Fremgangsmåde og sammensætning til behandling af cancer, drab på metastatiske cancerceller og forebyggelse af cancermetastaser under anvendelse af antistof mod avancerede glykeringsslutprodukter (age) |
| US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP6671555B2 (ja) | 2017-02-08 | 2020-03-25 | アーデーセー セラピューティクス ソシエテ アノニム | ピロロベンゾジアゼピン抗体複合体 |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| RS63502B1 (sr) | 2017-04-18 | 2022-09-30 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| WO2018229222A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3867277A4 (en) * | 2018-10-18 | 2022-09-07 | Sinomab Bioscience Limited | METHODS OF MODULATION OF AUTOIMMUNITY BY INTERFERING WITH CIS LIGAND BINDING OF SIGLEC-TYPE ANTIGENS |
| BR112021018260A2 (pt) | 2019-03-15 | 2021-11-23 | Medimmune Ltd | Dímeros de azetidobenzodiazepina e conjugados compreendendo-os para uso no tratamento de câncer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| CA2195557C (en) * | 1994-08-12 | 2006-10-17 | Shui-On Leung | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| DK1194167T3 (da) * | 1999-06-09 | 2009-11-16 | Immunomedics Inc | Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer |
| PL216630B1 (pl) * | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| WO2007103469A2 (en) * | 2006-03-06 | 2007-09-13 | Aeres Biomedical Ltd. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| SI2032606T1 (sl) * | 2006-05-30 | 2014-02-28 | Genentech, Inc. | Protitelesa in imunokonjugati in njihove uporabe |
| US8283162B2 (en) * | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
-
2010
- 2010-08-25 US US12/868,338 patent/US20110070227A1/en not_active Abandoned
- 2010-08-26 BR BR112012006035A patent/BR112012006035A2/pt not_active IP Right Cessation
- 2010-08-26 IN IN2196DEN2012 patent/IN2012DN02196A/en unknown
- 2010-08-26 CN CN2010800412158A patent/CN102574920A/zh active Pending
- 2010-08-26 JP JP2012529137A patent/JP5816905B2/ja not_active Expired - Fee Related
- 2010-08-26 KR KR1020127009393A patent/KR20120100914A/ko not_active Ceased
- 2010-08-26 ES ES10751563.7T patent/ES2608661T3/es active Active
- 2010-08-26 MX MX2012002907A patent/MX341117B/es active IP Right Grant
- 2010-08-26 CA CA2774244A patent/CA2774244A1/en not_active Abandoned
- 2010-08-26 WO PCT/EP2010/005225 patent/WO2011032633A1/en not_active Ceased
- 2010-08-26 EP EP10751563.7A patent/EP2478012B1/en active Active
- 2010-08-26 EA EA201270433A patent/EA026902B1/ru not_active IP Right Cessation
- 2010-08-26 AU AU2010294905A patent/AU2010294905B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP5816905B2 (ja) | 2015-11-18 |
| CN102574920A (zh) | 2012-07-11 |
| AU2010294905A1 (en) | 2012-04-05 |
| BR112012006035A2 (pt) | 2019-09-24 |
| EA026902B1 (ru) | 2017-05-31 |
| EP2478012B1 (en) | 2016-11-09 |
| KR20120100914A (ko) | 2012-09-12 |
| AU2010294905B2 (en) | 2016-09-22 |
| EP2478012A1 (en) | 2012-07-25 |
| ES2608661T3 (es) | 2017-04-12 |
| EA201270433A1 (ru) | 2012-10-30 |
| WO2011032633A1 (en) | 2011-03-24 |
| JP2013505205A (ja) | 2013-02-14 |
| IN2012DN02196A (index.php) | 2015-08-21 |
| US20110070227A1 (en) | 2011-03-24 |
| MX2012002907A (es) | 2012-04-30 |
| CA2774244A1 (en) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341117B (es) | Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab. | |
| MX2011011925A (es) | Anticuerpos triespecificos o tetraespecificos. | |
| CA145237S (en) | Combined cover and saucer | |
| CA141065S (en) | Dual c clip | |
| CA144362S (en) | Combined dishwashing and scrubbing tool | |
| CA144229S (en) | Drinking flask | |
| CA144920S (en) | Bottle | |
| CA140016S (en) | Battery | |
| WO2014078866A3 (en) | Engineered immunoglobulins with extended in vivo half-life | |
| AU333675S (en) | Bottle | |
| AU333674S (en) | Bottle | |
| MY159398A (en) | Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide | |
| WO2012106407A3 (en) | Diagnostic and therapeutic methods and products related to anxiety disorders | |
| CA147873S (en) | Teapot | |
| CA144263S (en) | Toy construction cell component | |
| AU327974S (en) | Bottle | |
| CA143665S (en) | Boot | |
| CA141066S (en) | Dual c clip | |
| AU327952S (en) | Bottle | |
| CA138917S (en) | Beverage package | |
| MY161868A (en) | Anti-bv8 antibodies and uses thereof | |
| CA143664S (en) | Boot | |
| AU327953S (en) | Bottle | |
| CA144264S (en) | Toy construction cell component | |
| AU327989S (en) | Bottle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |